

Regd. Office :

'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

<p>BSE Limited 1st Floor, P.J. Towers Dalal Street Mumbai – 400 001</p> <p>Kind Attn.: Mr. Sanjay Golecha / Mr. Gopalkrishnan</p>	<p>National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) Mumbai – 400 051</p> <p>Kind Attn.: Famroze Pochara Asst. Vice President</p>
<p>Date: March 30, 2016</p>	
<p>Re.: Press Release.</p>	


Dear Sir / Madam,

We enclose herewith a copy of press release dated March 30, 2016 under the title **“Zydus’ Nesher Pharmaceuticals, receives its first ANDA approval for Dextroamphetamine IR Tabs which will be manufactured at the Nesher Plant, USA”**. The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors’ at large.

Thanking you,

Yours faithfully,
For Cadila Healthcare Limited


Upen H. Shah
Company Secretary



Encl.: As above.

Zydus' Nesher Pharmaceuticals receives its first ANDA approval for Dextroamphetamine IR Tabs

The drug will be manufactured at the Nesher Plant, USA

Ahmedabad, 30 March 2016

Nesher Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA has received its first ANDA approval from the USFDA to market Dextroamphetamine IR Tabs. The drug falls in the CNS stimulant segment and is the first product to be developed by the R&D team at Nesher. The drug will be produced at the manufacturing facility based at St. Louis, Missouri, USA. The estimated sales for Dextroamphetamine IR Tabs is \$40.6 mn as per IMS.

Nesher has considerable expertise in niche therapies which have development or production barriers, such as controlled release medications or DEA-controlled substances, which otherwise cannot be imported.
